Symphogen has developed a proprietary expression platform called Sympress™, which enables the Company to produce consistent mixtures of polyclonal antibodies. Sympress™ is based on mammalian expression technology, e.g. by using the Chinese Hamster Ovary (CHO) and site-specific integration technology to generate antibody-producing cell lines. This technology makes it possible to maintain diversity and obtain batch-to-batch consistency when producing a polyclonal mixture.

View large illustration

The process involves culturing a mixture of cell lines, each of which expresses one distinct antibody. The Sympress™ technology also includes novel protein assays developed to characterize this new class of drug, which are needed for quality control and regulatory approval.

Symphogen has demonstrated proof-of-concept for the effective utilization of the Sympress™ manufacturing platform for multiple internally developed products. Besides Symphogen has issued and pending patents covering the production of recombinant polyclonal antibodies.